thiazolyl-methoxyiminoacetamido-3-desacetoxy-cephalosporin. The Ro 15-8074 structure most closely resembles two currently used parenteral cephalosporins, ceftizoxime and desacetylcefotaxime. The 7'-substitutions provide for an increased Ro 15-8074 antimicrobial activity against the Enterobacteriaceae, Haemophilus influenzae, and Neisseria spp. compared with currently available orally administered cephalosporins (2, 7, (9) (10) (11) ). An additional feature of Ro 15-8074 is its P-lactamase stability (9) . Unlike the clinically available orally administered cephalosporins, Ro 15-8074 requires a prodrug pivaloyloxymethylester to provide adequate gastrointestinal absorption (2, 11) .
In The results of testing enteric organisms are presented in Fig. 1 . Ro 15-8074 was generally 2-to >8-fold more active than either cefuroxime or cefaclor against the 16 tabulated species or groups of Enterobacteriaceae. If an MIC of <8 ,ug/ml was used to indicate susceptibility to all three cephalosporins, Ro 15-8074 would inhibit (MIC for 50% of strains tested [MIC50]) 15 of 16 organism groups. Only the Enterobacter spp., Citrobacterfreuhdii, Morganella morganii, and Serratia marcescens strains had .7% resistance to Ro 15-8074. None of cephalosporins were active against P. aeruginosa and Pseudomonas maltophilia (data not shown).
Ro 15-8074 had an MIC of '8 pLg/ml against approximately three-fourths of the Acinetobacter strains. Ro 15-8074 was also active against nine strains of Aeromonas hydr,phila (MIC50, 0.5 ,ug/ml) and against Pseudomonas cepacia (MIC50, 4.0 ,ug/ml).
The seven P-lactamase preparations used in the hydrolysis study minimally inactivated Ro 15-8074 and cefotaxime, the aminothiazolyl-methoxyimino cephalosporins.
The continued search for orally absorbed cephalosporins with expanded antimicrobial spectra has produced several new agents, including the cefuroxime axetil ester, LY164846, and cefixime (FK 027) (1, (3) (4) (5) . Each has a selected spectrum or potency advantage over earlier oral cephems such as cephalexin or cefaclor, but their serum concentrations generally remain lower (3, 4) . We also found Ro 15-8074 to have a somewhat unique antimicrobial spectrum directed principally against the enteric bacilli (13). The drug inhibited 90 .7% of all Enterobacteriaceae tested at c8 ,ug/ml compared with only 78.4 and 70.1% for cefuroxime and cefaclor, respectively. This activity advantage may be less pronounced if the absorption of the Ro 15-8074 ester does not produce concentrations in serum, compatible with an MIC breakpoint of <8 pLg/ml. This latter breakpoint is used for cephalexin, cephradine, cefadroxil, and cefaclor, but it was necessary to reduce the breakpoint to 1.0 Fg/ml for cefixime because of inferior oral pharmacokinetics (3) .
Studies reported elsewhere showed Ro 15-8074 to be very active against H. influenzae and Neisseria gonorrhoeae, including P-lactanmase-producing strains (7, 9, 10, 13 
